These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 23124289)

  • 41. Towards immunotherapy for chronic hepatitis B virus infections.
    Michel ML
    Vaccine; 2002 Dec; 20 Suppl 4():A83-8. PubMed ID: 12477434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recognition of HBV antigens and HBV DNA by dendritic cells.
    Cui GY; Diao HY
    Hepatobiliary Pancreat Dis Int; 2010 Dec; 9(6):584-92. PubMed ID: 21134826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune response pattern varies with the natural history of chronic hepatitis B.
    Wang WT; Zhao XQ; Li GP; Chen YZ; Wang L; Han MF; Li WN; Chen T; Chen G; Xu D; Ning Q; Zhao XP
    World J Gastroenterol; 2019 Apr; 25(16):1950-1963. PubMed ID: 31086463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. T-cell therapy for chronic viral hepatitis.
    Bertoletti A; Tan AT; Koh S
    Cytotherapy; 2017 Nov; 19(11):1317-1324. PubMed ID: 28847469
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides.
    Akbar SM; Al-Mahtab M; Khan MS
    Expert Opin Biol Ther; 2013 Jul; 13(7):1063-74. PubMed ID: 23581572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activation and Exhaustion of Adaptive Immune Cells in Hepatitis B Infection.
    Gogoi D; Borkakoty B; Biswas D; Mahanta J
    Viral Immunol; 2015 Sep; 28(7):348-53. PubMed ID: 26331345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatments of chronic hepatitis B aiming to HBs seroclearance].
    Tsuge M; Chayama K
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():535-9. PubMed ID: 26845992
    [No Abstract]   [Full Text] [Related]  

  • 48. Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.
    Suslov A; Wieland S; Menne S
    Curr Opin Virol; 2018 Jun; 30():9-17. PubMed ID: 29444493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peptide vaccines against hepatitis B virus: from animal model to human studies.
    Engler OB; Dai WJ; Sette A; Hunziker IP; Reichen J; Pichler WJ; Cerny A
    Mol Immunol; 2001 Dec; 38(6):457-65. PubMed ID: 11741695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus.
    Pagliaccetti NE; Robek MD
    J Interferon Cytokine Res; 2010 Aug; 30(8):585-90. PubMed ID: 20645875
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathogenesis of hepatitis B virus infection.
    Chisari FV; Isogawa M; Wieland SF
    Pathol Biol (Paris); 2010 Aug; 58(4):258-66. PubMed ID: 20116937
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts.
    Faure-Dupuy S; Lucifora J; Durantel D
    Viruses; 2017 Apr; 9(5):. PubMed ID: 28452930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges.
    Michel ML; Deng Q; Mancini-Bourgine M
    J Hepatol; 2011 Jun; 54(6):1286-96. PubMed ID: 21238516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis B Virus Surface Antigen Activates Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism.
    van Montfoort N; van der Aa E; van den Bosch A; Brouwers H; Vanwolleghem T; Janssen HLA; Javanbakht H; Buschow SI; Woltman AM
    J Virol; 2016 Jul; 90(14):6187-6199. PubMed ID: 27099316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. What once was lost, now is found: restoration of hepatitis B-specific immunity after treatment of chronic hepatitis B.
    Koziel MJ
    Hepatology; 1999 Apr; 29(4):1331-3. PubMed ID: 10094984
    [No Abstract]   [Full Text] [Related]  

  • 56. Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection.
    Bihl F; Loggi E; Chisholm JV; Biselli M; Morelli MC; Cursaro C; Terrault NA; Bernardi M; Bertoletti A; Andreone P; Brander C
    Liver Transpl; 2008 Apr; 14(4):478-85. PubMed ID: 18324666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
    Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
    Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression.
    Kawashima K; Isogawa M; Hamada-Tsutsumi S; Baudi I; Saito S; Nakajima A; Tanaka Y
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Corticosteroid withdrawal therapy in patients with chronic hepatitis B virus infection].
    Akuta N; Kumada H
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():345-8. PubMed ID: 15453343
    [No Abstract]   [Full Text] [Related]  

  • 60. Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies.
    Isorce N; Lucifora J; Zoulim F; Durantel D
    Antiviral Res; 2015 Oct; 122():69-81. PubMed ID: 26275801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.